BioStock: Elicera’s CEO: “One of the biggest milestones in our history”

Elicera Therapeutics has officially entered clinical trials with its drug candidate ELC-301. This CAR T-cell therapy is being evaluated in a phase I/IIa study on patients with hard-to-treat B-cell lymphomas, mantle cell lymphoma, or indolent lymphomas where standard treatments have failed. By launching the CARMA study, Elicera takes a significant step forward, advancing cancer treatment and positioning itself as a pioneer in Swedish CAR T-cell research.

Read the interview at biostock.se:

https://www.biostock.se/en/2024/11/eliceras-ceo-one-of-the-biggest-milestones-in-our-history/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/